<DOC>
	<DOCNO>NCT00511602</DOCNO>
	<brief_summary>Primary objective evaluate effect 12-week treatment period prandial administration Technosphere Insulin glucose control subject T2 DM . Secondary objective Evaluate safety tolerability 12-week treatment period Technosphere Insulin Technosphere Placebo .</brief_summary>
	<brief_title>Study Efficacy Safety Inhaled Technosphere Insulin Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Clinical diagnosis T2 DM &gt; 2 year &lt; 12 year duration Insulin treatment naive treat diet/exercise single/combination oral antidiabetic agent , metformin , sulfonylurea , and/or thiazolidinediones Stable regimen &gt; 3 month oral antidiabetes medication prior enrollment HbA1c &gt; 6.6 % &lt; 10.5 % BMI &lt; 38 kg/m2 1880 year age Baseline FVC FEV1 &gt; 80 % &lt; 120 % predict normal measured spirometry Baseline DLCO &gt; 80 % &lt; 120 % predict normal Clinical diagnosis type 1 diabetes mellitus Subjects currently use insulin therapy time screen Known hypersensitivity study drug drug similar chemical structure Fasting plasma glucose &gt; 270 mg/dL without adequate explanation transient causality ( screen could repeat 2week interim period ) History severe multiple allergy History tobacco nicotine test screening Severe complication diabetes include history blindness Stage III IV diabetic retinopathy , history renal failure require dialysis transplantation , history amputation limbs digit relate diabetic vasculopathy Treatment another investigational drug within 3 month prior study entry ( duration study ) Use medication know modify glucose metabolism decrease ability recover hypoglycemia oral , parenteral , inhaled steroid , beta blocker , exception beta blocker ophthalmic solution glaucoma ocular hypertension , hydrochlorothiazide ( HCTZ ) dose &gt; 25 mg/day Recent loss ( within 2 month prior screen ) &gt; 5 % body weight Evidence moderate great ketone urine ketoacidosis screen History chronic obstructive pulmonary disease history know chronic pulmonary disease reactive airway disease , chronic bronchitis , emphysema , asthma Diagnosis AIDS ARC A major psychiatric disorder would preclude satisfactory participation study Subjects myocardial infarction stroke within precede six month Prior diagnosis systemic autoimmune collagen vascular disease require heart disease grade Class III Class IV accord New York Heart Association criteria Prior treatment , participation , clinical study involve inhaled insulin product History malignancy within 5 year study entry ( basal cell carcinoma ) Significant hepatic disease ( evidenced ALT AST &gt; 3 time reference normal range bilirubin &gt; 1.5 time reference normal range ) Significant renal disease ( evidenced creatinine &gt; 1.5 mg/dL male &gt; 1.3 mg/dL female ) , proteinuria evidence great `` small '' dipstick measurement &gt; 2 gram 24 hour , dialysis , history renal transplant History previous current treatment systemic corticosteroid , cytotoxic drug , penicillamine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>